OKYO Pharma to Present at OIS XV in San Diego

Core Insights - OKYO Pharma Limited is focused on developing urcosimod for treating neuropathic corneal pain (NCP), a condition with no FDA-approved therapy [1][3][4] - The company will present at the Ophthalmology Innovation Summit (OIS) XV, highlighting its commitment to addressing unmet medical needs in the ophthalmic field [1][2][4] Company Overview - OKYO Pharma Limited is a clinical stage biopharmaceutical company listed on NASDAQ, dedicated to innovative therapies for NCP and dry eye disease [7] - The company is advancing urcosimod through clinical trials, including a recent Phase 2 trial that demonstrated promising results [3][6][7] Product Details - Urcosimod is a lipidated peptide designed to treat NCP, showing anti-inflammatory and pain-relieving effects in previous trials [3][6] - The drug is currently being evaluated in a multi-center clinical trial involving 120 patients, following positive top-line results from an earlier Phase 2 trial [3][4] Industry Context - The Ophthalmology Innovation Summit (OIS) XV is a key event for stakeholders in the eye care field, focusing on advancements in ophthalmic innovation [2] - The summit provides a platform for networking and sharing insights among innovators, investors, and clinicians [2]